Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
6-K
Earnings release
confidence 92%
filed 2026-07-09
EX-99.1
This is a press release announcing Triple Flag's Q2 2026 financial results, disclosing revenue of US$129.2 million from 28,674 gold equivalent ounces sold, preliminary cost of sales, and updated 2026 GEOs guidance of 100,000 to 110,000 ounces. The document explicitly states "Triple Flag Delivers Strong Q2 2026 GEOs" and provides a detailed breakdown of quarterly results by commodity. While the results are preliminary and subject to final review, this is a discrete earnings announcement typical of an earnings_release event, not a periodic financial report filing.
View raw filing on EDGAR →
6-K
Exec Compensation
confidence 95%
filed 2026-07-09
EX-99.1
This announcement discloses the grant of 1,326,736 RSUs to 107 employees under the 2026 Share Scheme on July 9, 2026, representing 0.31% of issued shares. The disclosure details vesting schedules, clawback mechanisms, and the compensatory purpose of aligning employee interests with the Group's long-term development. This is a material equity compensation arrangement subject to Hong Kong Listing Rules Rule 17.06A-C, requiring board announcement and disclosure of the terms and conditions of the awards.
View raw filing on EDGAR →
6-K
Earnings release
confidence 92%
filed 2026-07-09
EX-99.1
This is a press release announcing Polestar's first-half 2026 retail sales results (30,423 cars, a record), with CEO commentary on business progress, retail network expansion to 235 sites, and upcoming product launches (Polestar 5 and Polestar 4). The disclosure of H1 and Q2 sales volumes with year-over-year comparisons is characteristic of an earnings or results announcement, material to investors assessing operational performance and growth trajectory.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-09
Item 7.01
FuelCell Energy announced an underwritten public offering of 10,714,286 shares of common stock at $21.00 per share, generating gross proceeds of $225 million. This is a registered direct equity issuance that dilutes existing shareholders. The company intends to use proceeds for capital expenditures, working capital, and general corporate purposes. The magnitude ($225 million) and dilutive nature of the offering make it material to investors assessing the registrant's capital structure and ownership.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-09
Item 8.01
MetaVia announced completion of dose titration in its Phase 1 Part 3 clinical trial for DA-1726, with all enrolled patients successfully reaching their highest target doses of 48 mg and 64 mg. Topline data is expected in Q4 2026, representing a material clinical development milestone for the clinical-stage biotech company.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-07-09
EX-99.1
This is a news release disclosing Fortuna Mining's Q2 2026 production results (72,217 gold equivalent ounces) and first-half 2026 production (145,089 GEO), with detailed operational metrics by mine and updates on growth initiatives. The release explicitly states "Fortuna reports second quarter 2026 production" and provides consolidated production figures, mine-by-mine breakdowns, and annual guidance confirmation—the hallmark structure of a quarterly earnings/production release. Material to investors assessing operational performance and guidance achievement.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-07-09
Item 2.02
Pure Cycle issued a press release on July 8, 2026 announcing financial results for the three and nine months ended May 31, 2026, disclosing net income of $2.9 million and $8.6 million (31% and 23% increases year-over-year), earnings per share of $0.12 and $0.36 (33% and 24% increases), and total revenue growth of 60% and 51% respectively, representing the twenty-eighth consecutive quarter of positive net income.
View raw filing on EDGAR →
8-K
Exec departure
confidence 92%
filed 2026-07-09
Item 5.02
Daniel R. Kozlowski resigned from the Board of Directors effective July 7, 2026, not due to disagreement with the registrant. Kozlowski was identified as a significant shareholder whose contributions have been greatly appreciated.
View raw filing on EDGAR →
6-K
Exec Compensation
confidence 92%
filed 2026-07-09
The 6-K discloses receipt of share-based incentive awards by nine senior managers and officers (including CFO Marco Wirén) on 2026-07-09, totaling approximately 860,000 shares transferred from treasury without consideration to settle equity-based incentive plan commitments. This constitutes executive compensation disclosure under the equity-grant category, material to investors assessing management incentive alignment and dilution.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 98%
filed 2026-07-09
Item 8.01
The Board of Trustees declared a monthly dividend of $0.225 per share payable on August 27, 2026 to shareholders of record as of July 31, 2026. This is a routine but material dividend declaration that affects shareholder returns and is a standard disclosure for a closed-end fund like KKR FS Income Trust.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 98%
filed 2026-07-09
Item 8.01
The Board of Trustees declared a monthly dividend of $0.175 per share on common shares, payable August 27, 2026 to shareholders of record as of July 31, 2026. This is a routine but material dividend declaration that affects shareholder returns and is typical disclosure for a closed-end fund like KKR FS Income Trust Select.
View raw filing on EDGAR →
6-K
Workforce Reduction
confidence 95%
filed 2026-07-09
EX-99.1
The exhibit announces a workforce reduction of approximately 19% of Bragg Gaming Group's global workforce, with anticipated annualized cost savings of €6 million and restructuring costs of €0.6 million in H2 2026. This is a material operational restructuring event that would affect a reasonable investor's assessment of the company's cost structure, cash generation trajectory, and operational efficiency. The disclosure explicitly describes "organizational and operational measures" and "personnel-related termination costs," fitting the workforce_reduction category.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-07-09
Item 5.02
Stephen L. Miller, Chief Operating Officer, notified the Company on July 7, 2026 that he would retire effective August 30, 2026 for health-related reasons. The principal disclosed action is a senior executive's departure from his role, making this an executive departure event. The COO position is material to investor assessment of the registrant's leadership and operational continuity.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-07-09
Item 5.07
Traws Pharma held its Annual Meeting of Stockholders on July 8, 2026, with stockholders voting on five proposals: election of seven directors, amendment to the 2021 Incentive Compensation Plan to increase available shares by 2,000,000, ratification of KPMG LLP as independent auditor, approval of warrant issuance under Nasdaq Rule 5635(d), and adjournment authority. All five proposals passed with detailed vote tallies disclosed.
View raw filing on EDGAR →
8-K
M&A activity
confidence 96%
filed 2026-07-09
Item 1.01
XWELL entered into a definitive Securities Purchase Agreement on July 6, 2026, to divest its XpresSpa Holdings and XpresTest businesses to an affiliate of Face Haus (Express Wellness Group, LLC) for a base purchase price of $13 million. This transformative strategic restructuring, requiring stockholder approval, repositions the company toward the national security sector and is expected to close in 2026.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 85%
filed 2026-07-09
Item 1.01
On July 2, 2026, the Company entered into a Fourth Amended and Restated Senior Secured Revolving Credit Agreement that extends the revolving period to July 2, 2030 and the maturity date to July 2, 2031. This material amendment to the existing credit facility modifies key terms including the removal of the Term SOFR Adjustment and affects the Company's financial obligations and borrowing capacity.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 95%
filed 2026-07-09
Item 7.01
MV Oil Trust announced a distribution of $0.593844 per unit ($6,829,206 total) payable July 24, 2026 to unitholders of record as of July 15, 2026. The disclosure explains NYSE due-bill procedures because the distribution exceeds 25% of unit price. This is a material dividend/distribution event to unitholders, disclosed via Item 7.01 Regulation FD Disclosure with supporting press release.
View raw filing on EDGAR →
6-K
Governance Other
confidence 85%
filed 2026-07-09
EX-99.1
Transparency notifications of large shareholding changes under Belgian law: Orin Hirchman's entities crossed the 10% threshold on June 10, 2026, acquiring 14,534,880 voting rights (14.55% of shares), while Resmed Inc. passively crossed downward below the 3% threshold.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-07-09
EX-99.3
Nyxoah announced preliminary unaudited financial results for Q2 2026, disclosing global net revenue of €7.7 million with 21% sequential growth, U.S. revenue of €5.2 million with 22% sequential growth, and full-year 2026 revenue guidance of €36–40 million.
View raw filing on EDGAR →
6-K
Operational Other
confidence 72%
filed 2026-07-09
EX-99.1
This is a corporate update disclosing execution of AI infrastructure agreements, post-closing implementation activities, deployment milestones, and governance enhancements including board/leadership recruitment and audit preparations. While it touches on operational strategy (AI infrastructure deployment), governance (board strengthening, internal controls), and financial reporting (annual audit), the primary substance is operational—the company is reporting progress on recently executed AI infrastructure deals and coordinating deployment. The disclosure is material as it updates investors on execution of a significant strategic transaction and governance improvements, but does not fit neatly into a specific event category (not a discrete M&A completion announcement, not a specific governance appointment, not a financial result), making `operational_other` the most appropriate classification.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-07-09
The Company entered into a subscription agreement on July 9, 2026 to issue 1,280,000 ordinary shares at $0.52 per share for $665,600 to an existing shareholder (ANRUITAI INVESTMENT LIMITED). The shares are being issued in an unregistered offshore transaction under Regulation S, which is a classic private placement (PIPE). This dilutive issuance is material as it increases outstanding shares from approximately 31.8 million to 33.1 million and raises capital for the registrant.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 98%
filed 2026-07-09
Item 8.01
Amazon closed the sale of approximately $24.9 billion in aggregate principal amount of debt securities across eight series of notes with maturities ranging from 2029 to 2066, pursuant to an underwriting agreement with major investment banks.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 98%
filed 2026-07-09
Item 1.01
AutoZone entered into an underwriting agreement on July 7, 2026 to issue and sell $850 million aggregate principal amount of 4.950% Notes due 2031. This is a material creation of a direct financial obligation through debt issuance, disclosed under Item 1.01 (Entry into a Material Definitive Agreement). The size and terms of the debt offering are material to investors assessing the company's capital structure and financial position.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-07-09
Item 8.01
Annovis announced full enrollment of its pivotal Phase 3 trial (NCT06709014) for buntanetap in early Alzheimer's disease, with 850 patients enrolled across 83 US clinical sites. This is a material operational milestone for a Phase 3 clinical-stage biotech company, as it represents a critical step toward potential regulatory approval and commercialization. The disclosure includes near-term data readout milestones (Q1 2027 symptomatic data, Q1 2028 disease-modifying data) and planned NDA submissions, which would directly impact the company's value and investor assessment.
View raw filing on EDGAR →
8-K
M&A activity
confidence 99%
filed 2026-07-09
Item 1.01
Enerpac Tool Group entered into a definitive Agreement and Plan of Merger on July 7, 2026, to acquire Specialized Fabrication Equipment Group LLC for approximately $451.4 million in cash plus $20.6 million in restricted stock units. The acquisition is expected to close in Q1 FY2027, subject to regulatory approvals including HSR Act clearance, and is expected to be accretive to fiscal 2027 adjusted EPS.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-09
Item 1.02
The filing discloses termination of the Agreement and Plan of Merger between Shutterstock and Getty Images on July 7, 2026, following Getty Images' decision not to proceed with the CMA-mandated sale of Shutterstock's editorial business. This is a material M&A event—the termination of a previously announced merger agreement—which materially affects the registrant's strategic direction and investor expectations. Item 1.02 is the designated disclosure item for termination of material definitive agreements, and the merger's collapse is clearly material to investors.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-07-09
Item 8.01
This disclosure announces a postponement of the shareholder vote on a proposed business combination between PCSC and Freenome Holdings, Inc., moving the Extraordinary General Meeting from July 9, 2026 to July 15, 2026. While the postponement itself is administrative, the underlying business combination is material M&A activity. However, the filing does not disclose completion, termination, or material changes to the Business Combination Agreement itself—only a procedural delay to allow supplemental disclosure. The event is material to investors because it affects the timing and process of a significant transaction, but it does not fit cleanly into the `ma_activity` category (which covers entry, completion, or termination) or `shareholder_vote_results` (which covers vote outcomes, not scheduling changes). The disclosure is governance-related but the postponement is not a governance event per se—it is a procedural adjustment tied to an M&A transaction.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-09
Item 5.02
Kristina Campbell was appointed to the Board of Directors effective July 6, 2026, as an independent director and designated as Chair of the Audit Committee. Campbell brings extensive fintech and digital asset experience from her roles as CFO at Ripple Labs, PayNearMe, and Wrapbook, and is designated as an Audit Committee Financial Expert.
View raw filing on EDGAR →
8-K
Governance Other
confidence 75%
filed 2026-07-09
Item 1.01
The company entered into a material definitive Indemnification Agreement with directors and executive officers, establishing governance-related contractual protections and arrangements for board members and officers.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-07-09
Item 8.01
Ionis announced that its Phase 3 CARDIO-TTRansform trial for eplontersen failed to meet its primary efficacy endpoint of composite cardiovascular mortality and recurrent cardiovascular events in ATTR-CM patients, though a nominally significant result was observed in a prespecified monotherapy subgroup. This represents a material clinical trial failure for a key pipeline asset that significantly impacts the company's commercial prospects and strategic direction in ATTR-CM treatment.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-07-09
Item 2.01
Bed Bath & Beyond completed its acquisition of The Container Store Holdings, LLC on July 8, 2026, pursuant to a Merger Agreement dated April 2, 2026. The transaction consideration included 13.7 million shares of Common Stock and $112.6 million in Convertible Senior Notes due 2033, with TCS surviving as a wholly owned subsidiary.
View raw filing on EDGAR →
8-K
Financial Other
confidence 75%
filed 2026-07-09
Item 1.02
DevvStream terminated a material definitive agreement with Karbon-X to purchase $2.89 million in carbon credits in exchange for 444,923 common shares. While the termination itself was mutual and penalty-free, the elimination of a material forward purchase obligation affecting both cash and equity commitments is a financial event material to investors. This does not fit the specific categories of debt issuance, dilutive issuance (which contemplates actual equity sales), or M&A activity, so financial_other is most appropriate.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-07-09
EX-99.1
IperionX announced the pricing of a public offering of 2,275,000 ADSs (representing 22,750,000 ordinary shares) at $21.98 per ADS for approximately $50 million in gross proceeds. This is a registered public offering of equity securities that will dilute existing shareholders. The disclosure explicitly states the offering is being made pursuant to a shelf registration statement on Form F-3, making this a registered dilutive issuance material to investors assessing ownership and capital structure.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 85%
filed 2026-07-09
Item 8.01
The filing discloses material stockholder litigation and threatened litigation related to the pending merger. Two complaints were filed in New York state court on June 24, 2026 alleging negligent misrepresentation and concealment regarding proxy statement disclosures, and eleven demand letters threatening litigation were received between April 29 and July 1, 2026. Additionally, a Delaware Section 220 demand for inspection of books and records was received on July 8, 2026. Although the company denies liability and made supplemental disclosures to avoid litigation delays, the existence of actual filed complaints and multiple threatened actions constitutes material litigation disclosure under Item 8.01.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-07-09
Item 3.01
Prairie received a Nasdaq Minimum Bid Price Notice on July 2, 2026, indicating that its common stock closing bid price has been below the required $1.00 per share for 30 consecutive business days. The company has been granted an initial 180-day compliance period (until December 29, 2026) to regain compliance, with potential delisting consequences if it fails. This is a classic delisting-risk disclosure under Item 3.01, materially affecting investor assessment of the registrant's continued listing status.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-07-09
EX-99.1
This is a press release announcing Q2 2026 gold production results (176,836 ounces) and year-to-date production (374,464 oz), with guidance confirmation for full-year 2026 production of 700,000–800,000 oz. The release discloses operational metrics and production performance across multiple mines, which are core financial and operational results material to investors assessing the registrant's performance and ability to meet guidance.
View raw filing on EDGAR →
6-K
Earnings release
confidence 75%
filed 2026-07-09
EX-99.1
This is an announcement of an upcoming earnings release and conference call for Q2 2026 results scheduled for August 12–13, 2026. While the actual financial results are not disclosed in this exhibit, the press release announces the timing and logistics of the earnings announcement, which is a standard precursor to an earnings event. The disclosure identifies the CEO and CFO who will discuss performance, making it material to investors planning to access the results.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-07-09
Item 2.02
NTIC disclosed consolidated financial results for the third fiscal quarter ended May 31, 2026, via a press release attached as Exhibit 99.1. The disclosure includes quarterly net sales ($24.2M, up 12.6%), gross profit margins (down 477 basis points), and net loss per diluted share ($0.03 vs. prior year income of $0.01). This is a standard quarterly earnings release material to investors assessing the company's operational and financial performance.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-07-09
EX-99.1
Anfield announced a Mining Lease Agreement dated July 1, 2026, with Gold Eagle Mining Inc. for two additional patented mining claims in Colorado (Slick Rock Claim and Paradox D Claim). The lease expands the company's land holdings for the JD-5 and Slick Rock projects and will be integrated into mine design and permitting activities. This is a material operational/strategic event involving acquisition of mining rights that supports the company's hub-and-spoke uranium-vanadium development strategy, though it does not constitute a traditional M&A transaction (acquisition of a company or material asset sale/purchase) and is better classified as an operational expansion.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 92%
filed 2026-07-09
EX-99.1
The press release announces the issuance of approximately 15.7 million new warrants (New EIB Warrants) to the European Investment Bank at €0.01 per warrant, representing approximately 6.5% of the Company's current share capital on a non-diluted basis. This is a dilutive equity issuance that would materially affect shareholder ownership and voting rights. The transaction is part of a broader refinancing and capital structure optimization, and the warrants are exercisable from August 30, 2026 through January 4, 2036, creating future dilution potential.
View raw filing on EDGAR →
6-K
M&A activity
confidence 92%
filed 2026-07-09
EX-99.1
This press release announces completion of Phase 2 of a three-phase Option Agreement with Denison Mines, whereby Foremost increases its ownership interest from 20% to 51% across 10 Athabasca uranium projects (35.78% at Hatchet Lake). The transaction involves issuance of 848,610 shares valued at $2 million and completion of $8 million in exploration expenditures, representing a material change in Foremost's ownership and control of significant mineral assets. This constitutes a material acquisition or change of control event under the ma_activity category.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 92%
filed 2026-07-09
EX-99.1
CAE announces a voluntary transfer of its U.S. stock exchange listing from the NYSE to the Nasdaq Global Select Market, effective July 23, 2026. While this is a voluntary transfer rather than an involuntary delisting, it constitutes a material change in listing venue that affects where and how the company's shares trade in the U.S. market. The disclosure explicitly states the last trading day on NYSE (July 22, 2026) and commencement on Nasdaq (July 23, 2026), making this a transfer of listing under Item 3.01 framework, which is material to investors' ability to trade the security.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-07-09
The 8-K discloses fiscal 2027 first quarter financial results via press release (Item 2.02), with detailed financial metrics including net revenues of $4.8 million (down from $7.1 million), net loss of $(1.4) million, and loss per share of $(0.16). The filing explicitly states the company "announced, via press release, fiscal 2027 first quarter financial results" and includes the full press release as Exhibit 99.1, which is the standard format for earnings releases.
View raw filing on EDGAR →
6-K
M&A activity
confidence 95%
filed 2026-07-09
NaaS Technology Inc. entered into a definitive Share Acquisition Agreement on July 9, 2026, to acquire 100% of the issued and outstanding shares of China Newlink Holding Limited for US$15,000,000 in newly issued Class A ordinary shares. This constitutes a material acquisition transaction requiring disclosure under Item 1.01 of Form 8-K (or equivalent 6-K disclosure). The transaction is binding, involves a substantial equity issuance (16 billion Class A shares / 5 million ADSs), and is subject to customary closing conditions including regulatory approvals and Audit Committee review.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 92%
filed 2026-07-09
Item 1.01
The filing discloses entry into a material definitive agreement—an amendment to an existing Loan and Security Agreement with Oxford Finance LLC that modifies the terms and availability of a $150 million non-dilutive term loan facility. The amendment extends the availability of the remaining $15 million of Term A Loans through December 31, 2026, and conditionally extends the availability of Term B and Term C Loans, along with modifications to revenue covenants and non-utilization fees. This is a material modification to the Company's direct financial obligations and capital structure.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-07-09
EX-99.1
Virax Biolabs announced an exclusive multi-country commercial supply agreement with Fosun Diagnostics covering six Southeast Asian markets for its ImmuneSelect product line. This is a material strategic partnership and commercial milestone that establishes a framework for immediate product supply and revenue opportunities, representing a significant operational and commercial development for the company's business expansion in the ASEAN region.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-09
Item 5.02
The filing discloses the appointment of Nancy Bowman, M.D., Ph.D., as Chief Regulatory Officer effective August 3, 2026, succeeding William Turner. While Turner's transition to Special Advisor represents a departure from his CRO role, the principal disclosed action centers on the appointment of a new CRO—a material executive officer position at a therapeutic company where regulatory affairs are critical to operations and strategy.
View raw filing on EDGAR →
8-K
Earnings release
confidence 92%
filed 2026-07-09
Item 7.01
Forte Biosciences issued a press release on July 9, 2026 announcing positive Phase 1b clinical trial results for FB102 in vitiligo, including statistically significant efficacy endpoints (29.6% mean FVASI improvement, p=0.020) and safety data through week 24 post-treatment.
View raw filing on EDGAR →
8-K
Earnings release
confidence 92%
filed 2026-07-09
Item 2.02
The filing discloses a press release announcing year-to-date customer order activity through June 30, 2026, showing a significant 32% increase to approximately $268 million compared to $204 million in the prior-year period. This is a quantitative disclosure of operational and financial performance metrics for the first half of 2026, which is the hallmark of an earnings or results announcement under Item 2.02. While technically reporting "order activity" rather than completed earnings, this represents material financial condition disclosure that would affect a reasonable investor's assessment of the company's performance trajectory.
View raw filing on EDGAR →
6-K
Debt Issuance
confidence 92%
filed 2026-07-09
EX-99.1
This press release announces the final results of exchange offers whereby Shell Finance US exchanged $6.298 billion in aggregate principal amount of unregistered restricted notes for newly registered exchange notes. While technically an exchange rather than a new issuance, the creation of new registered debt obligations and the material principal amount involved ($6.3 billion across six note series with maturities from 2028 to 2051) constitutes a material debt transaction. The disclosure of the specific series, amounts tendered, and settlement date (July 13, 2026) aligns with Item 2.03 debt issuance disclosure requirements.
View raw filing on EDGAR →